

Atty. Dkt. No. 072827-1905

Amendments to the Claims


Please add new claims 25-27, as indicated below in the listing of claims. Please cancel claims 1-4 and 7-20 without prejudice.

Listing of Claims

This listing of claims will replace all prior versions, and listings, of claims in the application.

1-4. (Cancelled)

5. (Previously presented) A method of treating a patient for depression comprising administering to said patient an effective amount of a compound having the following chemical structure:



wherein X¹ is either -Br, -Cl, -F, -I, -CF₃, alkyl, -OH,

—OCF₃, -O-alkyl, or -O-acyl;

X² is either -Br, -Cl, -F, -I, -CF₃, alkyl, -OH, —OCF₃,

-O-alkyl, or -O-acyl; and

R³ is either -H or -CH₃;

or a pharmaceutically acceptable salt thereof.

Atty. Dkt. No. 072827-1905

6. (Original) The method of claim 5, wherein X^1 is -F, -Cl, -OCF₃ or -CF₃; and X^2 is either 2-OCH₃, 2-CH₃, 3-F, 3-CF₃, or 4-CF₃.

7-20. (Cancelled)

21. (Previously presented) The method of claim 5, wherein X^1 and X^2 are F, and R^3 is -H.

22. (Previously presented) The method of claim 21, wherein X^2 is at the 3-position.

23. (Previously presented) The method of claim 5, wherein X^1 and X^2 are F, and R^3 is -CH₃.

24. (Previously presented) The method of claim 23, wherein X^2 is at the 3-position.

25. (New) The method of claim 5, wherein said compound is active at a serotonin reuptake site and at a N-methyl-D-aspartate (NMDA) receptor.

26. (New) The method of claim 5, wherein said compound has an NMDA receptor IC₅₀ of about 50 nM to about 1 μ M.

27. (New) The method of claim 26, wherein said compound has an NMDA receptor IC₅₀ of about 100 nM to about 800 nM.